Microsoft word - molecules-14105-supplementary-final
Supplementary Material Modeling Chemical Interaction Profiles: II. Molecular Docking, Spectral Data-Activity Relationship, and Structure-Activity Relationship Models for Potent and Weak Inhibitors of Cytochrome P450 CYP3A4 Isozyme Table 1. Testing set of CYP3A4 inhibitors (120 compounds). Compound Compound Compound Compound
Chlormadinone Homochlorcyclizine Reserpine
Desloratadine Midecamycin Sulfinpyrazone
Table 2.Categorization of the 241 CYP3A4 inhibitors of Yap and Chen [33] by potency of CYP isozyme inhibition. Inhibitor of CYP isoform- Inhibitor of Drug Name -1A2 -2A6 -2B6 -2C8 -2C9 -2C19 -2D6 -2E1 -3A4 Inhibitor of CYP isoform- Inhibitor of Drug Name -1A2 -2A6 -2B6 -2C8 -2C9 -2C19 -2D6 -2E1 -3A4 Inhibitor of CYP isoform- Inhibitor of Drug Name -1A2 -2A6 -2B6 -2C8 -2C9 -2C19 -2D6 -2E1 -3A4 Inhibitor of CYP isoform- Inhibitor of Drug Name -1A2 -2A6 -2B6 -2C8 -2C9 -2C19 -2D6 -2E1 -3A4 Inhibitor of CYP isoform- Inhibitor of Drug Name -1A2 -2A6 -2B6 -2C8 -2C9 -2C19 -2D6 -2E1 -3A4 Inhibitor of CYP isoform- Inhibitor of Drug Name -1A2 -2A6 -2B6 -2C8 -2C9 -2C19 -2D6 -2E1 -3A4 Substrate of CYP isoform- Substrate of Drug Name -2C8 -2C9 -2C19 -2D6 other protein Substrate of CYP isoform- Substrate of Drug Name -2C8 -2C9 -2C19 -2D6 other protein Substrate of CYP isoform- Substrate of Drug Name -2C8 -2C9 -2C19 -2D6 other protein Substrate of CYP isoform- Substrate of Drug Name -2C8 -2C9 -2C19 -2D6 other protein Substrate of CYP isoform- Substrate of Drug Name -2C8 -2C9 -2C19 -2D6 other protein Substrate of CYP isoform- Substrate of Drug Name -2C8 -2C9 -2C19 -2D6 other protein
1 http://greenrxpharmacy.com/drug_information_contents.aspx?PN=Amprenavir 2 http://journals.lww.com/aidsonline/fulltext/2009/02200/pharmacology_of_second_line_antituberculosis_drugs.1.aspx 3 http://www.mybwmc.org/library/41/041355 4 http://www.hivmedicine.com/pdf/interact.pdf; Tseng A. www.tthhivclinic.com , General Hospital, Toronto, 2004. 5 http://www.p.kanazawa-u.ac.jp/~taisha/ejcp2000_843.pdf
6 http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#classInhibit 7 http://greenrxpharmacy.com/drug_information_contents.aspx?PN=Propofol 8 http://www.spine.org/Documents/fentora_9-13-07.pdf
Note: Most of the data were collected from The Merck Manual for Healthcare Professionals (http://www.merckmanuals.com/professional/index.html) as provided by Lexi-comp (http://lexi-comp.com/). 79 out 120 testing-set compounds were not included in the table because the information was not available. Information in the database is subject to change because it is based on clinical data that are continuously refined and updated. This table represents a snapshot of the database as of 2010.
DIARIO DE LOS PODER LEGISLATIVO DEL ESTADO LIBRE Y SOBERANO DE CHIHUAHUA LX LEGISLATURA NUMERO 64 Decimoctava Sesión del Segundo Período Ordinario de Sesiones, dentro del Segundo Año de EjercicioConstitucional, celebrada la mañana del Día 6 de Mayo de 2003, en el Recinto Oficial del PalacioLegislativo. 1.- LISTA DE ASISTENCIA Y APERTURA DE SESION. 2.- ORDEN DEL DIA. 3.- ACTA DE
PALUDISME : FEMME ENCEINTE ET NOUVEAU-NE Version : 0 Mots-clés : Paludisme, nouveau-né, femme enceinte Rédaction Relecture Validation 1: OBJECTIFS Faire le point des recommandations actuelles concernant le traitement curatif et préventif du paludisme de la femme enceinte et du nouveau-né . 2: DOMAINES D'APPLICATION Médecins et sage-femmes des services d